aeolus pharmaceuticals inc (AOLS) Key Developments
Aeolus Pharmaceuticals Inc. Receives Orphan Drug Designation from US FDA for AEOL 10150 for Treatment of Idiopathic Pulmonary Fibrosis
Mar 17 15
Aeolus Pharmaceuticals Inc. announced that it has received notice from the Office of Orphan Products Development at the U.S. Food & Drug Administration granting Orphan Drug Designation for AEOL 10150 'for treatment of idiopathic pulmonary fibrosis'. Orphan Drug Designation entitles the sponsor to a seven-year marketing exclusivity period, clinical protocol assistance with the FDA, as well as federal grants and tax credits. The company is also developing AEOL 10150 as a treatment for cancer patients receiving radiation therapy and for the pulmonary and delayed effects of acute radiation exposure under a five-year contract with the Biomedical Advanced Research and Development Authority, a division of the U.S. Department of Health and Human Services.
Aeolus Pharmaceuticals, Inc. Announces Unaudited Consolidated Financial Results for the First Quarter Ended December 31, 2014
Feb 13 15
Aeolus Pharmaceuticals Inc. announced unaudited consolidated financial results for the first quarter ended December 31, 2014. For the quarter, the company reported a net loss of approximately $698,000 or $0.01 per share compared to $695,000 or $0.01 per share, for the three months ended December 31, 2013. Revenue was approximately $925,000 versus revenue of $793,000 for the three months ended December 31, 2013. Loss from operations was $698,000 against $695,000 a year ago. Net cash used in operating activities was $1,070,000 against $335,000 a year ago.
Aeolus Pharmaceuticals Inc. Announces Consolidated Earnings Results for the Fourth Quarter and Full Year Ended September 30, 2014
Dec 22 14
Aeolus Pharmaceuticals Inc. announced consolidated earnings results for the fourth quarter and full year ended September 30, 2014. For the fourth quarter of fiscal year 2014, total revenues were $2,417,000 as compared to $883,000 in the fourth quarter of fiscal year 2013. Net loss for the fourth quarter in fiscal year of 2014 was $524,000 or ($0.0/share) as compared to $668,000 or ($0.0/share) in the fourth quarter of fiscal year 2013.
For the year, the company reported contract revenue of $9,631,000 compared to $3,928,000 a year ago. Loss from operations was $80,000 compared to $2,698,000 a year ago. Net loss was $80,000 or $0.00 per basic and diluted share compared to $3,208,000 or $0.03 per basic and diluted share a year ago. Net loss attributable to common stockholders was $80,000 compared to $3,208,000 a year ago. Net cash provided by operating activities was $323,000 compared to net cash used in operating activities of $2,970,000 a year ago.
Aeolus Pharmaceuticals Inc. Auditor Raises 'Going Concern' Doubt
Dec 22 14
Aeolus Pharmaceuticals Inc. filed its 10-K on Dec 22, 2014 for the period ending Sep 30, 2014. In this report its auditor, Grant Thornton, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Aeolus Pharmaceuticals Inc. Presents at 8th Annual OneMedForum 2015, Jan-13-2015 11:00 AM
Dec 19 14
Aeolus Pharmaceuticals Inc. Presents at 8th Annual OneMedForum 2015, Jan-13-2015 11:00 AM. Venue: San Francisco Marriott Marquis, Parc 55 Wyndham, Union Square, San Francisco, California, United States. Speakers: David C. Cavalier, Chairman of The Board, Chief Financial Officer and Secretary.